U.S. Capital Wealth Advisors LLC Lowers Position in Bristol Myers Squibb Company (NYSE:BMY)

U.S. Capital Wealth Advisors LLC lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,730 shares of the biopharmaceutical company's stock after selling 11,502 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Bristol Myers Squibb were worth $1,752,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pinney & Scofield Inc. bought a new stake in Bristol Myers Squibb during the 4th quarter worth $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth about $26,000. Fairway Wealth LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth about $28,000. Transce3nd LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth about $28,000. Finally, Global Wealth Strategies & Associates lifted its holdings in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares during the period. Institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on BMY shares. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group decreased their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Finally, Argus raised Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $58.00.

Insider Activity at Bristol Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president directly owned 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Bristol Myers Squibb Stock Up 0.9%

BMY stock traded up $0.44 during trading on Thursday, reaching $48.10. 5,355,829 shares of the stock were exchanged, compared to its average volume of 13,413,186. The firm's 50 day moving average is $47.60 and its 200 day moving average is $53.42. Bristol Myers Squibb Company has a twelve month low of $39.92 and a twelve month high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The firm has a market cap of $97.88 billion, a P/E ratio of 18.02, a price-to-earnings-growth ratio of 1.39 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business's revenue was down 5.6% on a year-over-year basis. During the same period last year, the company earned ($4.40) earnings per share. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.16%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.